ResearchCarboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
ResearchEnzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
ResearchEvaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy
ResearchEvolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
ResearchPhase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809)
ResearchComparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing
ResearchWOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide
ResearchSteroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs
ResearchTrial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
ResearchIntegrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors
ResearchLandscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes
ResearchCytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)